A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a dual PI3K delta/gamma inhibitor, in Patients with Relapsed or Refractory T-cell Lymphoma

UCI-16-45
NCT02567656
Cancer - Mycosis Fungoides, Cancer - Non-Hodgkin's Lymphoma
Lauren C Pinter-Brown
Open
Treatment
I
Adult
Local

For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.